Tyrosine-protein kinase inhibitors (e.g. sorafenib, regorafenib, lenvatinib, and nivolumab)-based liver cancer therapies are considered the most efficient targeted drugs for advanced HCC (Cheng et al., 2009; Yau et al., 2009; El-Khoueiry et al., 2017). This evidence concerns the gene WEE1 and hepatocellular carcinoma.